Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$15.71 -0.18 (-1.13%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Bausch + Lomb Stock (NYSE:BLCO)

Key Stats

Today's Range
$15.67
$16.07
50-Day Range
$15.92
$18.85
52-Week Range
$13.16
$21.69
Volume
196,959 shs
Average Volume
672,860 shs
Market Capitalization
$5.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.83
Consensus Rating
Hold

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

BLCO MarketRank™: 

Bausch + Lomb scored higher than 76% of companies evaluated by MarketBeat, and ranked 414th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 5 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 29.11% in the coming year, from $0.79 to $1.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -17.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -17.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bausch + Lomb's valuation and earnings.
  • Percentage of Shares Shorted

    4.98% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 37.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.98% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 37.30%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Bausch + Lomb this week, compared to 5 articles on an average week.
  • Search Interest

    3 people have searched for BLCO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.15% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    Only 11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

Bausch + Lomb (NYSE:BLCO) Earns Buy Rating from HC Wainwright
HC Wainwright Lowers Earnings Estimates for Bausch + Lomb
Nvidia > DeepSeek
Everyone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long run … that's a good thing.
Bausch + Lomb price target lowered to $17 from $18 at Stifel
Bausch + Lomb price target lowered to $17 from $18 at JPMorgan
Bausch + Lomb reports Q4 adjusted EPS 25c, consensus 23c
Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $18.06 at the beginning of 2025. Since then, BLCO stock has decreased by 12.9% and is now trading at $15.7360.
View the best growth stocks for 2025 here
.

Bausch + Lomb Co. (NYSE:BLCO) posted its earnings results on Wednesday, February, 19th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. The business's revenue was up 9.1% compared to the same quarter last year.

Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Bausch + Lomb's top institutional shareholders include Maple Rock Capital Partners Inc. (0.90%), Alberta Investment Management Corp (0.85%), D. E. Shaw & Co. Inc. (0.53%) and River Road Asset Management LLC (0.43%).
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include PayPal (PYPL), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Walt Disney (DIS), Intel (INTC) and Devon Energy (DVN).

Company Calendar

Last Earnings
2/19/2025
Today
2/21/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.83
High Stock Price Target
$25.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+25.5%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-6.00%

Debt

Sales & Book Value

Annual Sales
$4.79 billion
Cash Flow
$1.85 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
351,940,000
Market Cap
$5.57 billion
Optionable
Optionable
Beta
0.46
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:BLCO) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners